|
1
|
Walcott BP, Nahed BV, Mohyeldin A, Coumans
JV, Kahle KT and Ferreira MJ: Chordoma: Current concepts,
management, and future directions. Lancet Oncol. 13:e69–e76. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pan Y, Lu L, Chen J, Zhong Y and Dai Z:
Analysis of prognostic factors for survival in patients with
primary spinal chordoma using the SEER Registry from 1973 to 2014.
J Orthop Surg Res. 13:762018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kayani B, Hanna SA, Sewell MD, Saifuddin
A, Molloy S and Briggs TW: A review of the surgical management of
sacral chordoma. Eur J Surg Oncol. 40:1412–1420. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Le Cesne A, Chevreau C, Perrin C, Italiano
A, Hervieu A, Blay JY, Piperno-Neumann S, Saada-Bouzid E, Bertucci
F, Firmin N, et al: Regorafenib in patients with relapsed advanced
or metastatic chordoma: Results of a non-comparative, randomised,
double-blind, placebo-controlled, multicentre phase II study. ESMO
Open. 8:1015692023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu H, Lei C, He Q, Pan Z, Xiao D and Tao
Y: Nuclear functions of mammalian MicroRNAs in gene regulation,
immunity and cancer. Mol Cancer. 17:642018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Breulmann FL, Hatt LP, Schmitz B, Wehrle
E, Richards RG, Bella ED and Stoddart MJ: Prognostic and
therapeutic potential of microRNAs for fracture healing processes
and non-union fractures: A systematic review. Clin Transl Med.
13:e11612023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shao Y, Song X, Jiang W, Chen Y, Ning Z,
Gu W and Jiang J: MicroRNA-621 acts as a tumor radiosensitizer by
directly targeting SETDB1 in hepatocellular carcinoma. Mol Ther.
27:355–364. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shao Y, Zhang D, Li X, Yang J, Chen L,
Ning Z, Xu Y, Deng G, Tao M, Zhu Y and Jiang J: MicroRNA-203
increases cell radiosensitivity via directly targeting Bmi-1 in
hepatocellular carcinoma. Mol Pharm. 15:3205–3215. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shi L, Zhu W, Huang Y, Zhuo L, Wang S,
Chen S, Zhang B and Ke B: Cancer-associated fibroblast-derived
exosomal microRNA-20a suppresses the PTEN/PI3K-AKT pathway to
promote the progression and chemoresistance of non-small cell lung
cancer. Clin Transl Med. 12:e9892022. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li H, Zhang N, Jiao X, Wang C, Sun W, He
Y, Ren G, Huang S, Li M, Chang Y, et al: Downregulation of
microRNA-6125 promotes colorectal cancer growth through
YTHDF2-dependent recognition of N6-methyladenosine-modified GSK3β.
Clin Transl Med. 11:e6022021. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu Z, Wu K, Gu S, Wang W, Xie S, Lu T, Li
L, Dong C, Wang X and Zhou Y: A methyltransferase-like
14/miR-99a-5p/tribble 2 positive feedback circuit promotes cancer
stem cell persistence and radioresistance via histone deacetylase
2-mediated epigenetic modulation in esophageal squamous cell
carcinoma. Clin Transl Med. 11:e5452021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Long C, Jiang L, Wei F, Ma C, Zhou H, Yang
S, Liu X and Liu Z: Integrated miRNA-mRNA analysis revealing the
potential roles of miRNAs in chordomas. PLoS One. 8:e666762013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hu L, Xie X, Xue H, Wang T, Panayi AC, Lin
Z, Xiong Y, Cao F, Yan C, Chen L, et al: MiR-1224-5p modulates
osteogenesis by coordinating osteoblast/osteoclast differentiation
via the Rap1 signaling target ADCY2. Exp Mol Med. 54:961–972. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Alam H, Li N, Dhar SS, Wu SJ, Lv J, Chen
K, Flores ER, Baseler L and Lee MG: HP1γ promotes lung
adenocarcinoma by downregulating the transcription-repressive
regulators NCOR2 and ZBTB7A. Cancer Res. 78:3834–3848. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu M, Huang F, Zhang D, Ju J, Wu XB, Wang
Y, Wang Y, Wu Y, Nie M, Li Z, et al: Heterochromatin protein
HP1gamma promotes colorectal cancer progression and is regulated by
miR-30a. Cancer Res. 75:4593–4604. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ma C, Nie XG, Wang YL, Liu XH, Liang X,
Zhou QL and Wu DP: CBX3 predicts an unfavorable prognosis and
promotes tumorigenesis in osteosarcoma. Mol Med Rep. 19:4205–4212.
2019.PubMed/NCBI
|
|
20
|
Chang C, Liu J, He W, Qu M, Huang X, Deng
Y, Shen L, Zhao X, Guo H, Jiang J, et al: A regulatory circuit
HP1γ/miR-451a/c-Myc promotes prostate cancer progression. Oncogene.
37:415–426. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pamir MN and Ozduman K: Tumor-biology and
current treatment of skull-base chordomas. Adv Tech Stand
Neurosurg. 33:35–129. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huo X, Ma S, Wang C, Song L, Yao B, Zhu S,
Li P, Wang L, Wu Z and Wang K: Unravelling the role of immune cells
and FN1 in the recurrence and therapeutic process of skull base
chordoma. Clin Transl Med. 13:e14292023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hanna SA, Aston WJ, Briggs TW, Cannon SR
and Saifuddin A: Sacral chordoma: Can local recurrence after
sacrectomy be predicted? Clin Orthop Relat Res. 466:2217–2223.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Iorio MV and Croce CM: microRNA
involvement in human cancer. Carcinogenesis. 33:1126–1133. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ma YS, Yu F, Zhong XM, Lu GX, Cong XL, Xue
SB, Xie WT, Hou LK, Pang LJ, Wu W, et al: miR-30 family reduction
maintains self-renewal and promotes tumorigenesis in
NSCLC-initiating cells by targeting oncogene TM4SF1. Mol Ther.
26:2751–2765. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Slater SC, Jover E, Martello A, Mitić T,
Rodriguez-Arabaolaza I, Vono R, Alvino VV, Satchell SC, Spinetti G,
Caporali A and Madeddu P: MicroRNA-532-5p regulates pericyte
function by targeting the transcription regulator BACH1 and
angiopoietin-1. Mol Ther. 26:2823–2837. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bayrak OF, Gulluoglu S, Aydemir E, Ture U,
Acar H, Atalay B, Demir Z, Sevli S, Creighton CJ, Ittmann M, et al:
MicroRNA expression profiling reveals the potential function of
microRNA-31 in chordomas. J Neurooncol. 115:143–151. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen K, Chen H, Zhang K, Sun S, Mo J, Lu
J, Qian Z and Yang H: MicroRNA profiling and bioinformatics
analyses reveal the potential roles of microRNAs in chordoma. Oncol
Lett. 14:5533–5539. 2017.PubMed/NCBI
|
|
30
|
Huo X, Wang K, Yao B, Song L, Li Z, He W,
Li Y, Ma J, Wang L and Wu Z: Function and regulation of miR-186-5p,
miR-125b-5p and miR-1260a in chordoma. BMC Cancer. 23:11522023.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mosakhani N, Lahti L, Borze I,
Karjalainen-Lindsberg ML, Sundström J, Ristamäki R, Osterlund P,
Knuutila S and Sarhadi VK: MicroRNA profiling predicts survival in
anti-EGFR treated chemorefractory metastatic colorectal cancer
patients with wild-type KRAS and BRAF. Cancer Genet. 205:545–551.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Scarpati GD, Falcetta F, Carlomagno C,
Ubezio P, Marchini S, De Stefano A, Singh VK, D'Incalci M, De
Placido S and Pepe S: A specific miRNA signature correlates with
complete pathological response to neoadjuvant chemoradiotherapy in
locally advanced rectal cancer. Int J Radiat Oncol Biol Phys.
83:1113–1119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Qian J, Li R, Wang YY, Shi Y, Luan WK, Tao
T, Zhang JX, Xu YC and You YP: MiR-1224-5p acts as a tumor
suppressor by targeting CREB1 in malignant gliomas. Mol Cell
Biochem. 403:33–41. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang J, Wen T, Li Z, Che X, Gong L, Yang
X, Zhang J, Tang H, He L, Qu X and Liu Y: MicroRNA-1224 inhibits
tumor metastasis in intestinal-type gastric cancer by directly
targeting FAK. Front Oncol. 9:2222019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Canzio D, Larson A and Narlikar GJ:
Mechanisms of functional promiscuity by HP1 proteins. Trends Cell
Biol. 24:377–386. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mishima Y, Jayasinghe CD, Lu K, Otani J,
Shirakawa M, Kawakami T, Kimura H, Hojo H, Carlton P, Tajima S and
Suetake I: Nucleosome compaction facilitates HP1γ binding to
methylated H3K9. Nucleic Acids Res. 43:10200–10212. 2015.PubMed/NCBI
|
|
37
|
Bannister AJ, Zegerman P, Partridge JF,
Miska EA, Thomas JO, Allshire RC and Kouzarides T: Selective
recognition of methylated lysine 9 on histone H3 by the HP1 chromo
domain. Nature. 410:120–124. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cheutin T, McNairn AJ, Jenuwein T, Gilbert
DM, Singh PB and Misteli T: Maintenance of stable heterochromatin
domains by dynamic HP1 binding. Science. 299:721–725. 2003.
View Article : Google Scholar : PubMed/NCBI
|
